SecBot SecBot
SECBOTREPLAY Home › Report › PULM

PULM · PTC-2105 preclinical data

Pulmatrix, Inc. · 425 filed Nov 9, 2026 at 07:00 ET

At the news

NEUTRALIMPACT 3/10

425 filed Nov 9, 2026 at 07:00 ET

Eos SENOLYTIX announced new preclinical data for PTC-2105 showing it reduced semaglutide-associated lean-mass loss in aged mice, with the presentation upgraded to a plenary slot at an upcoming conference. The filing also confirms the merger with Pulmatrix remains on track for Q4 2026 close, subject to Nasdaq listing approval, after stockholder approval was obtained on October 26, 2026. The data is preclinical and promotional, with no changes to deal terms or financials.

  • Eos SENOLYTIX will present new preclinical data for PTC-2105 at the 19th Sarcopenia, Cachexia & Wasting Disorders International Conference in December 2026.
  • The presentation was upgraded from a poster to a plenary presentation.
  • PTC-2105 monotherapy reversed terminal lean-mass decline in aged high-fat-fed mice (+0.005 g/wk vs -0.002 g/wk for saline).
  • Co-administration of PTC-2105 with semaglutide reduced late-life lean-mass loss relative to semaglutide alone (+0.126 and -0.011 g/wk vs -0.055 g/wk).

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access